WGS GeneDx Holdings Corp.
Company Analysis
Latest News
🟢 GeneDx is trading 6.7% up today with no company-specific catalyst identified
GeneDx is trading 6.74% higher at $90.94, with the advance appearing primarily sector-driven. - Shares rebounded from a September 23 close of $85.20. - No...
🔴 GeneDx is trading 4.19% down today as yields and inflation concerns pressure biotech stocks
GeneDx is trading 4.19% lower at $87.00 as broad risk-off pressure weighs on growth-oriented healthcare stocks across the market. - No verified...
🔴 GeneDx is trading 10.2% down today: no verified company-specific catalyst
GeneDx is trading 10.2% down at $87.90, underperforming the broader biotechnology sector, which is higher on September 22, 2026; no verified same-day...
🔴 GeneDx is trading 5% down today with no clear company-specific catalyst
GeneDx is trading at $92.96, down -4.98%, with no credible same-day company-specific catalyst identified. - GeneDx declined despite broader markets trading...
🔴 GeneDx is trading 4.4% down today following a sharp multi-session advance
GeneDx is trading at $100.36, down -4.37%, after a sharp multi-session advance, with profit-taking or positioning possibly contributing. - GeneDx gained 7.73%...
🟢 GeneDx rises 4.2% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 GeneDx is trading 4.54% up today amid continued momentum
GeneDx is trading at $98.94, up 4.54%, with no major announcement or direct catalyst identified for September 16, 2026; the move suggests continued...
🟢 GeneDx is trading 4.22% up today; no clear catalyst identified
GeneDx is trading 4.22% up at $93.53, continuing its advance after rising 5.25% to $89.74 on September 14, 2026, with no clear company-specific catalyst...
🟢 GeneDx is trading 4.06% up today — no clear catalyst identified
GeneDx is trading 4.06% up at $88.73, with no major company-specific announcement or direct catalyst identified for September 14, 2026. - Participating in the...
🟢 GeneDx is trading 4.06% up today as major indexes gain more than 1%
GeneDx is trading 4.06% up at $87.37, moving alongside a broadly stronger market on September 11, 2026. - The S&P 500, Nasdaq Composite, and Dow Jones...
🟢 GeneDx is trading 4.12% up in pre-market — no clear company-specific catalyst found
GeneDx is trading at $88.30, up +4.12%, with no clear company-specific announcement found for September 2, 2026. • The latest identified catalyst was August 3...
🔴 GeneDx is trading 5.1% down today in pre-market as broad risk-off move hits U.S. futures
GeneDx is trading at $80.50 (-5.08%) after a broad risk-off move across U.S. equity futures. • S&P 500, Nasdaq Composite, and Dow futures are all lower. •...
🔴 GeneDx is trading 6% down today
GeneDx is trading 5.90% lower at $81.24 on August 31, 2026, with no clear company-specific catalyst identified. - No announcement, earnings update, analyst...
Casdin Capital increases GeneDx stake by 23%
Casdin Capital raised its stake in GeneDx Holdings (WGS) by 23.28% during the second quarter of 2026, according to a recent SEC filing. The investment firm,...
Bank of America boosts GeneDx stake, following surprise quarterly profit
Bank of America Corp DE increased its position in GeneDx Holdings Corp. during the first quarter. The bank purchased 102,456 additional shares, marking a 77.5%...
🟢 GeneDx rises 4.4% — Biotech Sector Continues Upward Trend on Strong Momentum
With Biotech (XBI) up 2.0%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 GeneDx is trading 4% up today despite broader biotech weakness
GeneDx is trading at $82.85, up +4.02%, with no fresh company-specific announcement identified to explain the August 20 move. - Recent bullish context...
GeneDx Faces Fiduciary Breach Investigation, Following Revenue Guidance Cut
Lifshitz Law Firm is investigating GeneDx Holdings Corp. for potential breaches of fiduciary duties by its directors and officers. This follows several similar...
🔴 GeneDx is trading 4.8% down in pre-market with no clear company-specific catalyst
GeneDx is trading 4.8% down at $75.83 after no clear company-specific catalyst emerged in the latest overnight coverage. - Recent developments—the August 11...
🟢 GeneDx rises 4.3% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...